ERBB2 and uterine carcinosarcoma: Trastuzumab is supposed to be effective for HER2-positive uterine carcinosarcoma patients, whereas anti-HER2 therapy in other gynecological malignancy does not have enough evidence to be efficacious which is under evaluation [4].